Chinook Therapeutics Inc.

Founded in 2019 and based in Washington, US, Chinook Therapeutics Inc. is a biotechnology company that develops therapeutics based on single-cell RNA (ribonucleic acid) sequencing, human-derived organoids, and new translational models for the treatment of kidney diseases. In August 2020, Chinook Therapeutics Inc. raised USD 106 million in PIPE funding from Ally Bridge Group, Avidity Partners, EcoR1 Capital, Janus Henderson Investors, Monashee Investment Management, Northleaf Capital Partners, OrbiMed Advisors, Rock Springs Capital, Sphera Funds Management, and Surveyor Capital.

In June 2020, Chinook and Aduro Biotech, Inc. announced a definitive merger agreement. After this transaction which was closed in the second half of 2020, Aduro was renamed Chinook Therapeutics, Inc. and trades on the Nasdaq under the ticker symbol KDNY.

In November 2021, Chinook Therapeutics Inc. raised USD 159. 6 million in a private placement, selling 11. 4 million shares at USD 14 per share on the Nasdaq.

Among the products in Chinook’s pipeline are Atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria. Chinook Therapeutics Inc.

plans to put the funding raised in August 2020 towards the phase 1 trial of CHK-336, and the advancement of additional research and discovery programs focused on the treatment of chronic kidney diseases.